Table 1 COX-1, COX-2, NF-KB and NO inhibitory activity and TNF-R2 binding activity (IC50) of EME, MCF and selected isolated compounds.
Extract/isolated compounds | COX-1* IC50 ± SD (µg/mL) | COX-2* IC50 ± SD (µg/mL) | TNF–R2* IC50 ± SD (ng/mL) | NF- KB* IC50 ± SD (Pg/mL) | NO* IC50 ± SD (µg/mL) |
|---|---|---|---|---|---|
Indomethacin (standard for COX-1) | 0.23 ± 0.00 | – | – | – | – |
Celecoxib (standard for COX-2) | ……. | 1.20 ± 0.00 | – | – | – |
Certolizumab | – | – | 6.70 ± 0.07 | – | – |
Curcumin | – | – | – | 7.80 ± 0.03 | – |
7- nitroindazole | – | – | – | – | 49.20 ± 0.80 |
Methanolic extract of E. maculata (EME) | 0.27 ± 0.01** | 1.37 ± 0.06 ** | 4.83 ± 0.03** | 5.77 ± 0.07 ** | 33.20 ± 0.80** |
Methylene chloride fraction (MCF) | 0.24 ± 0.01 | 1.86 ± 0.03 ** | 5.87 ± 0.09 ** | 6.73 ± 0.09 ** | 42.00 ± 2.50 |
Sakuranetin (C1) | 0.19 ± 0.01** | 3.23 ± 0.01** | 8.87 ± 0.09 ** | 10.07 ± 0.09 ** | 82.00 ± 1.06 ** |
Cinnamic acid (C2) | 0.16 ± 0.10** | 5.13 ± 0.01** | 7.63 ± 0.03 ** | 8.77 ± 0.07 ** | 66.00 ± 0.69 ** |
7-O-methyl aromadendrin (C4) | 0.22 ± 0.01 | 2.55 ± 0.02** | 8.33 ± 0.09 ** | 9.33 ± 0.03 ** | 76.40 ± 1.74 ** |
1,6- dicinnamoyl-O-α-D-glucopyranoside (C5) | 0.30 ± 0.01** | 1.16 ± 0.01** | 5.17 ± 0.07 ** | 6.07 ± 0.07 ** | 38.00 ± 0.04 ** |
